Back

A lower dose of liraglutide in patients with metabolic syndrome reduces epicardial adipose tissue, increases aerobic capacity and activates AMPK levels in circulating mononuclear cells.

29 August 2026 (09:15 - 10:00)
Organised by: Logo
Congress Presentation Part of: Diabetes and the heart: pharmacotherapy (2) Metabolic Syndrome, Insulin, Insulin Resistance ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Jorge E Jalil

Catholic University Clinical Hospital, Santiago (Chile)

5 More presentations in this session

Presentation thumbnail
Comprehensive risk factor control in the early stage of cardiovascular-kidney-metabolic syndrome to mitigate cardiovascular risk
Doctor X. Liu (Guangzhou, CN)
Presentation thumbnail
Association between early-stage systemic metabolic disorder and incident cardiometabolic treatment and cardiovascular hospitalisation in Japanese adults
Assistant Professor T. Adachi (Nagoya, JP)
Abstract Slides
Presentation thumbnail
Stress hyperglycemia exceeds known diabetes in predicting in-hospital mortality after acute myocardial infarction: An 11-year national study of 13,099 patients
Professor G. Bajraktari (Pristina, XK)
Abstract Slides
Presentation thumbnail
Associations of baseline cumulative and trajectory patterns of the cholesterol HDL glucose index with incident cardiovascular disease
Doctor J. Wei (Xi'an, CN)
Abstract Slides
Presentation thumbnail
High prevalence of undiagnosed abnormal glucose tolerance in patients with acute myocardial infarction in Northern Sweden
Professor G. Bajraktari (Pristina, XK)
Abstract Slides

Access the full session

Session thumbnail
Diabetes and the heart: pharmacotherapy (2)

The Event

Event poster

ESC Congress 2026

29 August 2026 09:15 CET
You may be interested in
thumbnail
Congress Presentation
Metabolic syndrome contributes to the pulmonary arterial dysfunction in pulmonary hypertension in heart failure with preserved ejection fraction
31 August 2020
thumbnail
Congress Presentation
Glucagon like peptide-1 receptor agonists and their combination with sodium-glucose cotransporter-2 inhibitors improve myocardial deformation and work index in type-2 diabetes after 12-month treatment
28 August 2020
thumbnail
Congress Presentation
Adipose and non-adipose layers of epicardium: paracrine activity consequences on cardiomyocytes and modulation by semaglutide
30 August 2025
thumbnail
Webinar
GLP-1 RAs and HFpEF: which HFpEF patients should now be receiving GLP-1 RAs?
15 December 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources